Product Development
Most cell and gene
therapy products are regulated as medicinal products in the EU and the US; as
such their development must result in data that confirm quality, safety and
efficacy.
One of the key objectives of Product
development, aside from
demonstration of clinical efficacy, is to fully understand the characteristics
of the product and the process used to make it. Characterisation is central to product development, this figure
provides an overview of the scope of characterisation activities and how they
interrelate.
Effective
development processes provide all the tools necessary to implement changes, and
these tools are a result of thorough characterisation. Implementation of
changes to the manufacture of medicinal products requires that the product
before and after the change is comparable. Comparability is
a central concept in the regulation of medicinal products; this tool provides
an overview of the various parameters that might be required for a
comparability exercise.
Instructions: Many of these
tools are interactive and can be expanded or collapsed by clicking on the
(+). Alternatively you can expand or collapse levels by right
clicking on the diagram and selecting the required level.
Links to external
documents are included and indicated by the following symbol Simply click to open the
document in a new tab.
Some tools contain notes, hover or click on
note symbol to see note.
Feedback
We value your
feedback; should you have comments or suggestions for inclusions and amendments
please let us know. Contact: info@advbiols.com
Acknowledgements
These tools were
developed with the support of a grant from the Technology Strategy Board as
part of the VALUE consortium (Regenerative Medicine Value Systems: Navigating
the Uncertainties) lead by Biolatris Ltd (http://www.biolatris.com).
|